Navigation Links
OctreoPharm Sciences Receives Orphan Drug Designation for SOMscan® for the Diagnosis of Neuroendocrine Tumours
Date:10/12/2011

BERLIN, October 12, 2011 /PRNewswire/ --

OctreoPharm Sciences GmbH, a Berlin based specialist for radiopharmaceuticals, announced today that the European Medicines Agency has granted Orphan Drug status to OctreoPharm Sciences product SOMscan® for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.

The Orphan Drug status entitles OctreoPharm Sciences to ten year market exclusivity in Europe following marketing approval for SOMscan®. The designation also provides for special benefits, including possible exemptions in certain regulatory fees during development.

"We are proud to have received this Orphan Drug Designation for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours" said Dr. Hakim Bouterfa, Managing Director and Head of R&D. Udo Blaseg, Managing Director and Head of Operations added: "This designation is an important step for a new and heavily improved diagnostic and staging tool for a seriously debilitating and potentially lethal disease."

About SOMscan™

SOMscan is a new Gallium-68-labeled radioactive contrast agent for positron emission tomography with the potential to detect neuroendocrine tumors currently in Phase I. It binds to four out of five specific tumor receptor subtypes on the surface of neuroendocrine tumors. This may allow detection of neuroendocrine tumors which previously escaped discovery in imaging. The diagnosis of neuroendocrine tumors with SOMscan has the potential to be faster, more accurate, more reliable and more specific.

About OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. The company intends to acquire licenses for other product candidates as well. OctreoPharm Sciences is in particular on the lookout for collaborations with pharmaceutical companies which focus on products for personalized medicine and new therapeutic agents.

Contact:
Udo Blaseg
OctreoPharm Sciences GmbH
Robert-Rössle-Straße 10
13125 Berlin
Phone:  +49(0)30-9489-3360
eMail:  info@octreopharm.com



'/>"/>
SOURCE OctreoPharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product
2. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
3. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
4. SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner
5. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
6. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
7. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
8. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
9. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
10. BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity
11. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
Breaking Medicine News(10 mins):